FMR1 and fragile X syndrome: A small-scale phase IIa, placebo-controlled clinical trial of 30 adult male patients with FXS suggested efficacy of mavoglurant in the subpopulation of patients with a fully methylated FMR1 gene16, which supported a larger-scale development program.